

May 12, 2026

To The Manager, Listing Department National Stock Exchange of India Ltd. Plot no. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai- 400 051 Symbol: BLISSGVS	To The General Manager, Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 506197
--	--

Dear Sir/Madam,

Subject: Outcome of Board Meeting held on Tuesday, May 12, 2026

We would like to inform you that the Board Meeting of the Company was held today i.e. on Tuesday, May 12, 2026, at the registered office of the Company. In pursuant to Regulation 30 and Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has considered and approved the following matters amongst others:

1. The Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026, along with the audit report of the auditors. The copy of the said financial and Audit Reports are enclosed herewith as '**Annexure-1**'.
2. Declaration of unmodified opinion for annual audited standalone and consolidated financial results for the year ended March 31, 2026, in accordance with Regulation 33(3)(d) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016, is enclosed herewith as '**Annexure - 2**';
3. Recommended Final dividend of 100%, i.e. 1 Rupee per equity share on face value of Rs. 1/- each for the financial year ended March 31, 2026, subject to approval of the shareholders in the forthcoming 41st Annual General Meeting of the Company ('**41st AGM**');
4. Re-appointment of M/s. BDO India Services Private Limited, as an Internal Auditor of the Company for the financial year 2026-27. The brief profile of the internal auditor is enclosed herewith as '**Annexure - 3**';
5. 41st Annual General Meeting ("**41st AGM or AGM**") of the Company for the financial year ended March 31, 2026 has been scheduled to be held on **Wednesday, July 15, 2026, at 11:00 A.M.** through Video Conferencing ('VC')/Other Audio Visual Means ('OAVM') facility pursuant to the Circular No.14 / 2020 dated April 8, 2020, Circular No. 17 / 2020 dated April 13, 2020 and Circular No. 20 / 2020 dated May 5, 2020 and all other related subsequent circulars issued in this regard and latest one being General Circular No. 03/2025 dated September 22, 2025, issued by the Ministry of Corporate Affairs ("**MCA Circulars**") which does not require physical presence of members at a common venue. The deemed venue for the 41st AGM shall be the registered office of the Company.

The Board of Directors meeting commenced at 5:05 PM and concluded at 7:30 PM.

Kindly take the above information on your record and acknowledge it.

Thanking you.

Yours faithfully,

For **Bliss GVS Pharma Limited**

Aditi Bhatt
Company Secretary

Encl: As above

KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

INDEPENDENT AUDITOR'S REPORT TO THE BOARD OF DIRECTORS OF BLISS GVS PHARMA LIMITED

Report on the Audit of the Standalone Financial Results

Opinion

We have audited the accompanying annual Standalone Financial Results of **BLISS GVS PHARMA LIMITED** ("the Company") for the year ended March 31, 2026, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"), duly initialled by us for identification.

In our opinion and to the best of our information and according to the explanations given to us, these Standalone Financial Results:

- i) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii) give a true and fair view in conformity with the recognition and measurement principles of applicable Indian Accounting Standards ("Ind AS"), and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information of the Company for the year ended March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Results* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Board of Directors' Responsibilities for the Standalone Financial Results

These Standalone Financial Results have been prepared on the basis of the annual standalone financial statements. The Company's Board of Directors are responsible for the preparation and presentation of these Standalone Financial Results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Board of Directors of the Company are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.



LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001
TEL.: (91) (22) 6158 6200, 6158 7200 FAX : (91) (22) 6158 6275

In preparing the Standalone Financial Results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to standalone financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the standalone financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Company regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



**KALYANIWALLA
& MISTRY LLP**


We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The Standalone Financial Results include the results for the quarter ended March 31, of the respective financial years, being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the end of the third quarter of the relevant financial year, which were subjected to limited review by us.

Our opinion on these Standalone Financial Results is not modified in respect of the above matter.

For KALYANIWALLA & MISTRY LLP
CHARTERED ACCOUNTANTS
Firm Regn. No. 104607W / W100166



Jamshed K. Udawadia
PARTNER

M. No.: 124658
UDIN: 26124658ZYHSOF9287
Mumbai: May 12, 2026.



KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

INDEPENDENT AUDITOR'S REPORT TO THE BOARD OF DIRECTORS OF BLISS GVS PHARMA LIMITED

Report on the Audit of the Consolidated Financial Results

Opinion

We have audited the accompanying annual Consolidated Financial Results of **BLISS GVS PHARMA LIMITED** (hereinafter referred to as the "the Holding Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as the "Group"), for the year ended March 31, 2026, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India ("the SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"), duly initialled by us for identification.

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate audited financial statements of the subsidiaries, the aforesaid, Consolidated Financial Results:

- i) include the financial results of the following entities:
 - A. **Incorporated in India:**
 1. Kremoint Pharma Private Limited, India
 - 1.1 Eipii Exports Private Limited, India (Subsidiary of 1. above)
 - B. **Incorporated outside India:**
 2. Bliss GVS International Pte. Ltd., Singapore
 - 2.1 Asterisk Lifesciences (GH) Limited, Ghana (Subsidiary of 2. above)
 - 2.2 Theralife Pharma Ltd, Kenya (Subsidiary of 2. above), with effect from November 25, 2025
 - 2.3 Theralife Pharma RDC Private Limited, Democratic Republic of the Congo (Subsidiary of 2. above), with effect from January 27, 2026
 3. Asterisk Lifesciences Limited (UK), United Kingdom
- ii) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations, in this regard; and
- iii) give a true and fair view in conformity with the recognition and measurement principles of the applicable Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Group for the year ended March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Results* section of our report. We are independent of the Group, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other



LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001
TEL.: (91) (22) 6158 6200, 6158 7200 FAX: (91) (22) 6158 6275

ethical responsibilities in accordance with these requirements and Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Board of Directors' Responsibilities for the Consolidated Financial Results

These Consolidated Financial Results have been prepared on the basis of the annual consolidated financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of these Consolidated Financial Results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group, are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group, and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Consolidated Financial Results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Consolidated Financial Results by the Board of Directors of the Holding Company, as aforesaid.

In preparing the Consolidated Financial Results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intend to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.



- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Consolidated Financial Results, including the disclosures, and whether the Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results of the entities within the Group to express an opinion on the Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial results of such entities included in the Consolidated Financial Results of which we are the independent auditors. For the other entities included in the Consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other Matters

- a) The Consolidated Financial Results include the audited financial results of three subsidiaries and two step-down subsidiaries, whose financial statements reflect Group's share of total assets (before consolidation adjustments) of Rs. 25,278.50 lakh as at March 31, 2026, Group's share of total revenues (before consolidation adjustments) of Rs. 8,056.21 lakh and Rs. 27,819.79 lakh, Group's share of total net profit after tax (before consolidation adjustments) of Rs. 576.20 lakh and Rs. 4,252.41 lakh, Group's share of total comprehensive income (before consolidation adjustments) of Rs. 335.96 lakh and Rs. 4,509.53 lakh for the quarter and year ended March 31, 2026, respectively and Group's share of cash inflows (net) of Rs. 1,260.07



**KALYANIWALLA
& MISTRY LLP**

lakh for the year ended March 31, 2026, as considered in the Consolidated Financial Results, which have been audited by their respective independent auditors.

The independent auditors' reports on financial statements of these entities have been furnished to us and our opinion on the Consolidated Financial Results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries / step down subsidiaries, is based solely on the reports of such auditors and the procedures performed by us are as stated in the paragraph above.

- b) The Consolidated Financial Results include the unaudited financial results of two step-down subsidiaries, whose financial statements reflects Group's share of total assets (before consolidation adjustments) of Rs. 2,534.28 lakh as at March 31, 2026, Group's share of total revenues (before consolidation adjustments) of Rs. 667.19 lakh and Rs. 667.19 lakh, Group's share of total net profit after tax (before consolidation adjustments) of Rs. 26.91 lakh and Rs. 24.36 lakh, Group's share of total comprehensive income (before consolidation adjustments) of Rs. 27.38 lakh and Rs. 24.83 lakh for the quarter and year ended March 31, 2026, respectively and Group's share of cash inflows (net) of Rs. 246.23 lakh for the year ended March 31, 2026 as considered in the Consolidated Financial Results. These unaudited financial results have been furnished to us by the Board of Directors and our opinion on these Consolidated Financial Results, in so far as it relates to the amounts and disclosures included in respect of such step-down subsidiaries is based solely on such unaudited financial statements. In our opinion and according to the information and explanations given to us by the Board of Directors, these financial statements are not material to the Group.


Our opinion on these Consolidated Financial Results is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the unaudited financial statements certified by the Board of Directors.

- c) The Consolidated Financial Results include the results for the quarter ended March 31, of the respective financial years, being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the end of the third quarter of the relevant financial year, which were subjected to limited review by us.

Our opinion on these Consolidated Financial Results is not modified in respect of the above matter.

**For KALYANIWALLA & MISTRY LLP
CHARTERED ACCOUNTANTS**

Firm Regn. No. 104607W / W100166


Anshu K. Udawadia
PARTNER

M. No.: 124658

UDIN: 26124658NOZVPN8740

Mumbai: May 12, 2026.





Statement of Audited Standalone and Consolidated Financial Results for the Quarter and Year ended March 31, 2026

* In Lakh

Sr. No.	Particulars	Standalone					Consolidated				
		Quarter Ended			Year Ended		Quarter Ended			Year Ended	
		Mar 31, 2026	Dec 31, 2025	Mar 31, 2025	Mar 31, 2026	Mar 31, 2025	Mar 31, 2026	Dec 31, 2025	Mar 31, 2025	Mar 31, 2025	Mar 31, 2025
		Audited	Un-Audited	Audited	Audited	Audited	Audited	Un-Audited	Audited	Audited	Audited
I	Revenue from Operations	21,153.73	16,458.07	15,600.74	72,980.76	66,720.46	25,690.32	21,825.19	19,798.58	92,711.28	80,972.62
II	Other Income	930.18	1,023.24	936.08	4,371.87	3,621.65	1,116.13	1,845.59	1,208.85	7,352.98	3,669.85
III	Total Income (III)	22,083.91	17,481.31	16,536.82	77,352.63	70,342.11	26,806.45	23,670.78	21,007.43	1,00,064.26	84,642.47
IV	Expenses										
a.	Cost of Materials Consumed	10,277.71	7,938.36	6,878.59	36,046.49	33,947.44	11,125.51	8,621.96	7,661.21	38,675.52	37,251.39
b.	Purchases of Stock-in-Trade	778.89	-	-	778.89	-	1,821.12	2,020.19	1,357.07	6,125.24	4,928.50
c.	Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(1,264.71)	(107.50)	918.83	(2,561.66)	663.23	(1,600.83)	(475.85)	928.63	(2,244.31)	(811.07)
d.	Employee Benefits Expense	3,183.18	3,180.63	2,522.46	12,149.78	9,941.28	3,613.81	3,593.55	2,824.38	13,642.75	11,705.04
e.	Finance Costs	181.14	147.53	129.98	1,211.36	658.38	200.75	148.60	167.79	1,200.68	812.00
f.	Depreciation and Amortisation Expenses	784.15	780.19	743.45	3,101.95	2,704.72	867.07	934.97	803.61	3,348.34	2,941.76
g.	Other Expenses	3,814.09	2,766.63	3,907.34	13,164.01	13,009.45	6,295.69	4,586.42	4,922.79	20,158.41	15,730.43
	Total Expenses	17,704.25	14,710.84	15,100.65	63,290.62	60,825.00	22,323.12	19,329.84	18,661.38	80,856.63	72,058.05
V	Profit before exceptional items and tax (III-IV)	4,379.66	2,770.47	1,436.17	13,562.01	9,417.11	4,483.33	4,340.94	2,346.05	19,207.63	12,584.42
VI	Less: Exceptional items	35.82	(251.37)	-	(215.54)	-	2.66	(251.37)	-	(248.71)	-
VII	Profit before Tax (V-VI)	4,343.84	2,519.10	1,436.17	13,346.47	9,417.11	4,480.67	4,089.57	2,346.05	18,958.92	12,584.42
VIII	Tax Expenses										
	Current Tax	1,099.64	752.19	467.92	4,142.49	3,073.77	1,076.40	1,455.50	662.57	6,807.23	4,012.73
	Deferred Tax	67.58	(83.80)	(104.43)	(596.69)	(478.90)	(1,188.11)	156.16	89.26	(1,433.12)	(399.18)
	Taxation adjustment of earlier years Excess(-)/Short(+)	6.01	-	(73.03)	111.22	(74.63)	6.83	-	(73.04)	112.04	(75.16)
IX	Net Profit for the period/ year (VII-VIII)	3,242.25	1,883.11	1,164.21	9,687.44	6,864.47	3,699.27	2,477.91	1,465.26	13,472.77	9,025.53
X	Other Comprehensive Income										
	I. Items that will not be re-classified to Profit or Loss										
	(i) Remeasurement of (loss)/ gain of Defined Benefit Plan	8.07	(24.10)	(19.07)	(24.00)	(74.45)	25.80	(24.10)	(20.57)	(6.27)	(75.95)
	(ii) Tax relating to items that will not be reclassified to Profit or Loss	(2.99)	7.02	4.79	6.04	18.73	(7.45)	7.02	5.17	1.58	19.11
	II. Items that will be re-classified to Profit or Loss										
	(i) Exchange differences in translating the financial statements of foreign operations	-	-	-	-	-	(415.30)	498.84	(45.15)	207.89	(237.99)
	(ii) Tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	156.84	(125.54)	11.73	-	60.27
XI	Total Comprehensive Income/ (Loss) for the period/ year	3,242.33	1,863.63	1,140.93	9,669.48	6,841.15	3,459.76	2,834.13	1,615.44	13,675.97	8,790.97
XII	Profit attributable to:										
	I. Owners of the Company	-	-	-	-	-	3,557.51	2,326.58	1,593.91	12,912.32	8,429.93
	II. Non-Controlling Interests	-	-	-	-	-	(312.36)	(511.33)	111.35	559.85	595.60
XIII	Other Comprehensive Income/ (Loss) attributable to:										
	I. Owners of the Company	-	-	-	-	-	(244.09)	356.22	(51.63)	199.22	(212.44)
	II. Non-Controlling Interests	-	-	-	-	-	3.98	-	2.81	3.99	(22.12)
XIV	Total Comprehensive Income/ (Loss) attributable to:										
	I. Owners of the Company	-	-	-	-	-	3,313.42	2,682.79	1,502.28	13,112.14	8,217.49
	II. Non-Controlling Interests	-	-	-	-	-	146.34	151.33	113.15	563.83	573.48
XV	Paid up equity share capital (Face Value ₹ 1/-)	1,057.89	1,057.89	1,057.89	1,057.89	1,057.89	1,057.89	1,057.89	1,057.89	1,057.89	1,057.89
XVI	Other Equity	-	-	-	1,14,460.93	1,04,809.61	-	-	-	1,16,232.07	1,03,983.86
XVII	Earnings Per Share Basic and Diluted (*Not Annualised) (%)										
	I. Basic	3.06*	1.76*	1.08*	9.17	6.56	3.37*	2.20*	1.47*	12.23	8.02
	II. Diluted	2.99*	1.72*	1.07*	8.00	6.50	3.28*	2.14*	1.46*	12.00	7.95






BLISS GVS PHARMA LIMITED
 Regd. Office - 102, Hyde Park, Saki Vihar Road, Andheri East- Mumbai-400072
 CIN - L24230MH1984PLC034771
 Balance Sheet as at March 31, 2026

₹ in Lakh

Particulars	Standalone		Consolidated	
	March 31, 2026	March 31, 2025	March 31, 2026	March 31, 2025
	Audited	Audited	Audited	Audited
ASSETS				
NON-CURRENT ASSETS				
Property, Plant and Equipment	41,934.24	36,766.47	45,068.08	39,700.72
Capital Work-in-Progress	439.82	2,058.18	604.63	2,071.10
Investment Property	68.13	68.29	68.13	68.29
Goodwill	-	-	771.11	771.11
Other Intangible Assets	20.07	22.06	21.42	23.03
Financial Assets				
- Investments	1,868.95	1,868.95	352.07	438.49
- Other Financial Assets	4,973.85	2,281.28	5,025.81	3,121.36
Income Tax Assets (Net)	237.12	241.80	304.22	327.75
Deferred Tax Assets (Net)	1,510.01	909.28	1,630.07	-
Other Non-Current Assets	730.01	1,223.70	762.15	1,223.70
TOTAL NON-CURRENT ASSETS	51,782.20	45,440.01	54,607.69	47,745.55
CURRENT ASSETS				
Inventories	11,091.75	8,193.88	15,073.40	12,572.96
Financial Assets				
- Investments	-	-	144.55	-
- Trade Receivables	45,711.71	42,869.89	51,719.17	43,880.32
- Cash and Cash Equivalents	333.25	682.80	3,514.16	2,379.39
- Bank balances other than Cash and Cash Equivalents	10,726.51	16,428.17	13,172.85	18,951.32
- Loans	2,861.18	3,698.91	3.51	4.03
- Other Financial Assets	7,251.89	1,936.29	5,857.95	890.48
Other Current Assets	4,659.45	2,764.32	5,148.05	2,987.30
TOTAL CURRENT ASSETS	82,635.74	76,574.26	94,633.64	81,665.80
Asset Classified as Held for Sale	-	-	-	717.24
TOTAL ASSETS	1,34,417.94	1,22,014.27	1,49,241.33	1,30,128.59
EQUITY AND LIABILITIES				
EQUITY				
Equity Share Capital	1,057.89	1,053.70	1,057.89	1,053.70
Other Equity	1,14,460.93	1,04,809.61	1,18,232.07	1,03,983.86
Non-Controlling Interest	-	-	3,885.97	4,147.09
TOTAL EQUITY	1,15,518.82	1,05,863.31	1,23,175.93	1,09,184.65
LIABILITIES				
NON-CURRENT LIABILITIES				
Financial Liabilities				
- Borrowings	-	1,967.29	-	1,984.57
- Lease Liabilities	902.04	1,247.14	1,330.10	1,271.52
- Other Financial Liabilities	838.21	-	838.21	-
Provisions	299.96	436.39	340.90	436.39
Deferred Tax Liabilities (Net)	-	-	-	29.95
Other non-current liabilities	-	-	2.02	4.71
TOTAL NON-CURRENT LIABILITIES	2,040.21	3,650.82	2,511.23	3,727.54
CURRENT LIABILITIES				
Financial Liabilities				
- Borrowings	-	3,133.60	292.62	5,112.91
- Lease Liabilities	420.84	423.99	552.31	440.99
- Trade Payables				
Total Outstanding Dues of Micro Enterprises and Small Enterprises	1,377.57	645.14	1,736.11	896.02
Total Outstanding Dues of Creditors other than Micro Enterprises and Small Enterprises	8,248.73	5,386.43	8,684.59	6,245.82
- Other Financial Liabilities	5,026.37	2,307.44	7,712.02	3,108.69
Other Current Liabilities	913.32	554.30	1,101.07	970.22
Provisions	468.74	49.24	475.03	64.40
Current Tax Liabilities (Net)	403.34	-	3,000.42	377.35
TOTAL CURRENT LIABILITIES	16,858.91	12,500.14	23,554.17	17,216.40
TOTAL LIABILITIES	18,899.12	16,150.96	26,065.40	20,943.94
TOTAL EQUITY & LIABILITIES	1,34,417.94	1,22,014.27	1,49,241.33	1,30,128.59





Particulars	Standalone		Consolidated	
	Year Ended		Year Ended	
	March 31, 2026	March 31, 2025	March 31, 2026	March 31, 2025
	Audited	Audited	Audited	Audited
A. CASH FLOW FROM OPERATING ACTIVITIES				
Profit before tax	13,966.46	9,417.11	13,966.92	12,563.92
Adjustments for:				
Exceptional items:	215.55	-	248.71	-
Depreciation and Amortisation expense	3,101.95	2,704.73	3,349.34	2,941.76
Finance costs	1,113.36	658.38	1,200.68	812.00
Interest income	(1,504.63)	(1,378.04)	(1,654.37)	(1,499.68)
Interest on Tax refund	-	(15.18)	-	(15.21)
Unwinding of discount on security deposits	(19.51)	-	(26.36)	-
Dividend income	(25.20)	(12.60)	-	-
Rent income	(2.02)	(1.99)	(6.52)	(1.99)
Profit on sale of investments measured at fair value through profit or loss (FVTPL) (Net)	(18.40)	(11.23)	(23.51)	(19.34)
(Profit)/ Loss on Disposal of Property, Plant and Equipment (Net)	(15.33)	31.94	(145.82)	49.20
Loss on Property, Plant and Equipment written off	50.98	-	52.95	-
Loss on Intangible Assets written off	1.28	-	1.25	-
Unrealised foreign exchange (gain)/ loss (Net)	(2,693.02)	(436.75)	(2,319.24)	(601.22)
Provision for Employee Benefits	150.79	323.40	165.94	332.58
Bad debts	401.97	-	1,341.18	-
Utilisation of Provision for Expected Credit Loss on Trade Receivable	(379.55)	-	(379.55)	-
Provision for Expected Credit Loss on Trade Receivables (Net)	875.10	833.90	1,455.69	1,240.38
Provision for Expected Credit Loss on Advances and Deposits (Net)	(0.11)	907.92	(0.11)	907.92
Deposits written off	0.70	-	0.70	-
Liabilities no longer required writeback	(49.75)	(79.54)	(49.75)	(80.35)
Inventory write off/ write down	1,487.70	1,398.32	1,706.60	2,317.19
Fair Value (gain)/ loss on financial assets measured at fair value through profit or loss (FVTPL) (Net)	3,481.14	306.58	3,481.14	306.58
Fair Value (gain)/ loss on investments measured at fair value through profit or loss (FVTPL) (Net)	-	-	(66.44)	(29.78)
Share Based Payment expenses	862.42	414.00	862.42	414.00
Loss on sale of Investments in Subsidiary	-	-	356.70	-
	7,033.31	5,645.83	9,586.67	7,074.56
Operating Profit before Working Capital changes	20,379.77	15,060.94	23,545.59	19,628.48
Movements in Working Capital:				
(Increase)/ Decrease in Trade Receivables	(1,403.33)	(3,378.26)	(8,836.50)	(4,158.06)
(Increase)/ Decrease in Inventories	(4,385.57)	(646.91)	(4,548.98)	(3,045.42)
(Increase)/ Decrease in Non-Current Financial Assets	97.24	(65.88)	73.99	(69.63)
(Increase)/ Decrease in Current Financial Assets	(300.35)	24.92	57.03	1.37
(Increase)/ Decrease in Other Non-Current Assets	(391.41)	(172.23)	(398.11)	(31.91)
(Increase)/ Decrease in Other Current Assets	(1,695.72)	1,666.78	(2,178.78)	1,903.61
(Increase)/ Decrease in Loans	-	-	0.11	2.80
Increase/ (Decrease) in Trade Payables	3,561.33	623.47	3,261.58	1,063.90
Increase/ (Decrease) in Other Current Financial Liabilities	258.58	(245.33)	2,142.11	(473.13)
Increase/ (Decrease) in Non-Current Provisions	(136.43)	(285.66)	(95.45)	(225.08)
Increase/ (Decrease) in Current Provisions	8.21	112.99	(48.69)	64.40
Increase/ (Decrease) in Current Liabilities	359.02	(141.75)	130.91	(195.29)
Increase/ (Decrease) in Non-Current Liabilities	-	-	(2.69)	(1.85)
	(4,218.43)	(2,307.88)	(10,444.51)	(5,145.61)
Cash generated from Operations	16,161.34	12,753.06	13,101.08	14,492.87
Income taxes paid (net)	(3,845.69)	(3,092.52)	(4,165.24)	(3,663.59)
Effects of exchange differences on translation of assets and liabilities	-	-	(64.06)	(257.99)
Net Cash generated from/ (used in) Operating Activities	12,315.65	9,720.54	13,871.78	10,591.29
B. CASH FLOW FROM INVESTING ACTIVITIES				
Purchase of Property, Plant and Equipment and Intangible Assets	(5,955.13)	(6,872.41)	(5,683.11)	(7,628.60)
Proceeds from Sale of Property, Plant and Equipment and Intangible Assets:	70.39	177.20	253.52	341.21
Change in bank balance other than cash and cash equivalents	4,136.62	(898.39)	4,213.42	282.82
(Purchase)/ Proceeds of Fixed Deposits (maturity > 12 months)	(5,989.37)	(1,615.25)	(5,177.15)	(2,227.48)
Interest received	1,428.39	1,395.87	1,697.96	1,643.64
Dividend received	23.20	12.60	-	-
Rent received on Investment Properties	2.02	1.99	6.52	1.99
Purchase of investments measured at fair value through profit or loss (FVTPL) (Net)	(5,875.09)	(3,566.00)	(5,881.00)	(3,627.99)
Proceeds from Sale of Investments measured at fair value through profit or loss (FVTPL) (Net)	5,893.40	3,597.23	5,912.82	3,655.67
Proceeds from repayment of Loan given to related party	1,123.20	-	-	-
Proceeds from sale of Investments in Subsidiary	-	-	851.95	-
Cash and cash equivalents of step down subsidiary discharged pursuant to sale of subsidiary	-	-	(22.30)	-
Net Cash generated from/ (used in) Investing Activities	(5,139.83)	(7,787.16)	(3,827.95)	(7,558.74)
C. CASH FLOW FROM FINANCING ACTIVITIES				
Proceeds from Secured and Unsecured Borrowings	150.00	5,004.36	425.34	5,527.31
Repayment of Secured and unsecured Borrowings	(4,836.59)	(6,467.03)	(6,436.56)	(7,174.67)
Repayment of Principal Portion of Lease Liabilities	(434.68)	(428.45)	(502.43)	(448.75)
Interest paid	(1,412.45)	(528.63)	(1,493.37)	(682.10)
Dividend paid	(1,063.65)	(539.48)	(1,063.65)	(539.47)
Dividend paid to non-controlling interests	-	-	(10.80)	(5.40)
Bank balance in unpaid dividend accounts	(19.65)	14.65	(19.64)	14.65
Proceeds from issue of Shares including Securities Premium	180.06	288.62	180.04	288.62
Net Cash generated from/ (used in) Financing Activities	(7,537.02)	(2,655.88)	(8,921.07)	(3,018.81)
Net increase/ (decrease) in Cash and Cash Equivalents (A+B+C)	(361.20)	(722.60)	1,122.75	12.74
Cash and Cash Equivalents at the beginning of the year	685.08	1,417.46	2,351.67	2,359.05
Effect of Exchange on restatement of Foreign Currency	9.37	(9.79)	9.74	9.87
Cash and Cash Equivalents at the end of year	333.25	685.08	3,514.16	2,381.67
Cash and Cash Equivalents comprises of:				
Balances with Banks				
In Current accounts	332.39	696.06	2,233.21	1,043.24
In Deposit accounts	-	14.79	1,269.17	1,326.06
Cash on hand	0.86	1.95	11.78	10.06
Add: Cash included under Current Financial Assets - Others	-	2.28	-	2.28
Cash and Cash Equivalents as per Statement of Cash Flows	333.25	685.08	3,514.16	2,381.67



Note:
 The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard (Ind AS 7) - "Statement of Cash Flows"

Notes:

- 1 The above audited standalone and consolidated financial results which are published in accordance with Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 12, 2026. These standalone and consolidated audited financial results have been prepared in accordance with recognition and measurement principles of Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and the other accounting principles generally accepted in India.
- 2 The above audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 have been audited by the statutory auditors of the Company. The statutory auditors have issued audited reports with unmodified opinion on the audited standalone and consolidated financial results.
- 3 As the Group's business activity falls within a single operating segment viz "Pharmaceutical and Healthcare", no segment information is disclosed.
- 4 Employee Benefit Expenses includes Share Based Payment expense on account of ESOP Scheme, 2019 of ₹.852.42 Lakh (year ended March 31, 2025 ₹ 414.00 Lakh) as per Ind AS 102 "Share based Payment" for the year ended March 31, 2026.
- 5 Pursuant to the implementation of the New Labour Codes with effect from November 21, 2025, the Company and the Group has reassessed its employee benefit obligations and recognised an incremental expense of ₹ 215.55 Lakh and ₹ 248.71 Lakh in standalone and consolidated financials respectively for the year ended March 31, 2026, under Exceptional Items as past service cost.
- 6 During the year ended March 31, 2026, the Company has allotted 4,18,700 equity shares of ₹ 1 each fully paid, on exercise of stock options by employees in accordance with the Company's ESOP Scheme, 2019. The outstanding number of options as at March 31, 2026 are 27,03,250.
- 7 The Board of Directors has recommended final dividend of ₹ 1 per share. The payment is subject to approval of shareholders in the ensuing Annual General Meeting of the Company.
- 8 The Board of Directors in its meeting held on May 12, 2025 had approve the sale of 51% stake in its step-down subsidiary, Greenlife Bliss Healthcare Ltd, Nigeria, held by its subsidiary, Bliss GVS International Pte Ltd, Singapore, to non-controlling shareholder for a total consideration of USD 13,00,000. As a result of said transaction, the Company has lost control on Greenlife Bliss Healthcare Ltd. w.e.f April 01, 2025, the said Company has not been considered for consolidation.
- 9 During the year ended March 31, 2026, Bliss GVS International Pte. Ltd., Singapore, a wholly owned subsidiary of the Company, has incorporated two wholly owned subsidiaries namely "Theralife Pharma Ltd.", in the Republic of Kenya dated November 25, 2025 and "Theralife Pharma RDC Private Limited", in Democratic Republic of the Congo dated January 27, 2026.
- 10 The figures of the previous year have been reclassified for better presentation to bring it in conformity with the current year classification. These reclassification do not have any impact on the profits or networth of the previous reported year.

₹ in Lakh

Particulars	Standalone		Consolidated	
	March 31, 2025		March 31, 2025	
	Reclassified	Reported	Reclassified	Reported
Trade Receivables	42,869.89	42,825.19	43,880.32	43,835.62
Income Tax Assets (Net) - Non-Current	241.80	-	327.75	-
Current Tax Assets (Net) - Current	-	239.45	-	312.35
Other Non-Current Assets	1,223.70	1,226.05	1,223.70	1,239.10
Other Current Financial liabilities	2,307.44	2,262.74	3,108.69	3,063.99

- 11 The figures for the quarter ended March 31 are the balancing figures between audited figures in respect of the year ended March 31 and the published year to date unaudited figures for the nine months ended December 31 of the respective financial years.

For BLISS GVS PHARMA LIMITED

Narsimha Shibroor Kamath
Managing Director
DIN : 00140593

Place : Mumbai
Date : May 12, 2026



May 12, 2026

To The Manager, Listing Department National Stock Exchange of India Ltd. Plot no. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai- 400 051 Symbol: BLISSGVS	To The General Manager, Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 506197
--	--

Subject: Declaration pursuant to Regulation 33(3)(d) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the annual audited financial results (Standalone and Consolidated) for the year ended March 31, 2026

Dear Sir/Madam,

We, Bliss GVS Pharma Limited, hereby declare that the statutory auditor has issued an audit report with Unmodified Opinion on audited Standalone and Consolidated financial results of the Company for the year ended March 31, 2026.

Kindly take the same on your record.

Thanking you.

Yours Faithfully,

For **Bliss GVS Pharma Limited**

Deepak Sawant
Chief Financial Officer

Brief Profile of the Internal Auditor of the Company

ABOUT BDO



BDO GLOBAL

- BDO's foundation was done in the year 1963, the initial international organisation was known as the Binder Seidman International Group, formed by respected firms.
- In 1973 the organisation adopted the name BDO, made up from the initials of the three founding European firms: Binder (UK), Dijker (Netherlands) and Otte (Germany).
- In the subsequent **50+ years**, BDO has grown into a **US\$15 billion+** business, extending in across **166 countries** and territories, with **119,611 people** working out of **1,800 offices** – and they're all working towards one goal: to provide our clients with exceptional service.

Our Global CEO

- Mr. Keith Farlinger

Our Awards are

- IAB Network of the Year
- BDO South Africa: Best Tax Firm of the Year, 2015
- BDO Australia: Best Provider-Client Choice Awards
- BDO Global Outsourcing: International Payroll Award
- BDO Sweden: BDO Ranked 1st for client Satisfaction
- BDO UK: Ranked Market Leader for client satisfaction

BDO:

- BDO India Services Private Limited ("BDO India") is the India member firm of BDO International.
- BDO India offers strategic, operational, accounting and tax & regulatory advisory & assistance for both domestic and international organisations across a range of industries. We are led by **more than 350 Partners & Directors** with a team of **over 11,000 professionals** operating across **14 cities**.

Our Key People are

- Mr. Milind Kothari, Managing Partner, BDO India

Auditors' Appointed & Date of Appointment:

- Mr. Hiren Upadhyay, Partner & Leader West, Business Advisory Services on May 12, 2026 for FY 2026-2027

Reason for change: Re-Appointment